Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and other central nervous system (CNS) conditions. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on improving existing stimulant-based therapies through novel drug delivery technologies rather than discovering new molecular entities.
The company’s primary business activity is the development of prescription drug candidates that leverage its proprietary Precision Timed Release (PTR™) platform, designed to provide predictable, multi-phase drug release over an extended period. Cingulate Inc. was incorporated in 2013 and later became publicly traded on the NASDAQ under the ticker CING following a business combination and public listing. Its strategy has consistently centered on addressing unmet needs in ADHD treatment, particularly the demand for long-duration symptom control with reduced variability.
Business Operations
Cingulate Inc. operates as a single-segment clinical-stage biopharmaceutical company and does not currently generate commercial product revenue. Its operations are focused on research and development activities, clinical trials, regulatory preparation, and intellectual property management related to its drug candidates. The company’s lead product candidates are CTx-1301 and CTx-1302, both based on well-established stimulant active pharmaceutical ingredients formulated using the PTR™ delivery technology.
The company’s activities are primarily conducted in the United States, with clinical trials, regulatory interactions, and corporate functions centered domestically. Cingulate Inc. relies on third-party contract research organizations, clinical trial sites, and manufacturing partners rather than owning manufacturing facilities. There is no verified public disclosure of material joint ventures or revenue-generating subsidiaries as of the most recent filings.
Strategic Position & Investments
The strategic direction of Cingulate Inc. is focused on advancing its lead ADHD candidates through clinical development toward potential regulatory approval. The company’s growth initiatives are centered on completing late-stage clinical trials, engaging with regulatory authorities, and preparing for potential commercialization either independently or through strategic partnerships. Its PTR™ technology is positioned as a differentiator, aiming to offer once-daily dosing with consistent therapeutic coverage throughout the day.
The company’s investment activities are primarily internal, directed toward clinical development and intellectual property protection rather than external acquisitions. There is no verified evidence of completed acquisitions or ownership of operating portfolio companies. While the PTR™ platform may have broader applicability across CNS disorders, public disclosures confirm that current development efforts remain concentrated on ADHD, and expansion into other indications remains exploratory.
Geographic Footprint
Cingulate Inc. is headquartered in the United States, with its corporate offices located in Kansas. Its operational footprint is largely domestic, reflecting its status as a development-stage biotechnology company focused on U.S. regulatory approval pathways. Clinical trial activities are conducted at multiple sites within the United States, supported by national research institutions and medical centers.
International operations are limited, with no verified evidence of foreign subsidiaries or material overseas commercial activities. However, the company’s intellectual property filings and long-term strategic outlook contemplate potential future market access beyond North America, subject to regulatory and partnership developments.
Leadership & Governance
Cingulate Inc. is led by an executive team with experience in pharmaceutical development, regulatory strategy, and corporate management. The leadership emphasizes disciplined clinical execution, capital efficiency, and leveraging established drug compounds with improved delivery profiles as a means of reducing development risk.
Key executives include:
- Shane J. Schaffer – Chief Executive Officer
- Shane J. Schaffer – President
- Joel Friedman – Chief Financial Officer (Data inconclusive based on available public sources regarding tenure and current status)
The company is governed by a board of directors with backgrounds in biotechnology, finance, and healthcare. While founder-specific attribution is disclosed in public filings, available sources indicate that strategic leadership continuity has been maintained since the company’s early development phase.